FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2964855288> ?p ?o ?g. }

• W2964855288 endingPage "770" @default.
• W2964855288 startingPage "761" @default.
• W2964855288 abstract "Background Nearly a quarter of patients with locally advanced (T4 stage) or perforated colon cancer are at risk of developing peritoneal metastases, often without curative treatment options. We aimed to determine the efficacy of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with locally advanced colon cancer. Methods This multicentre, open-label trial was done in nine hospitals that specialised in HIPEC in the Netherlands. Patients with clinical or pathological T4N0–2M0-stage tumours or perforated colon cancer were randomly assigned (1:1), with a web-based randomisation application, before resection of the primary tumour, to adjuvant HIPEC followed by routine adjuvant systemic chemotherapy (experimental group) or to adjuvant systemic chemotherapy alone (control group). Patients were stratified by tumour characteristic (T4 or perforation), age (<65 years or ≥65 years), and surgical approach of the primary tumour resection (laparoscopic or open). Key eligibility criteria included age between 18 and 75 years, adequate clinical condition for HIPEC, and intention to start adjuvant systemic chemotherapy. Patients with metastatic disease were ineligible. Adjuvant HIPEC consisted of fluorouracil (400 mg/m2) and leucovorin (20 mg/m2) delivered intravenously followed by intraperitoneal delivery of oxaliplatin (460 mg/m2) for 30 min at 42°C, delivered simultaneously or within 5–8 weeks after primary tumour resection. In all patients without evidence of recurrent disease at 18 months, a diagnostic laparoscopy was done. The primary endpoint was peritoneal metastasis free-survival at 18 months, measured in the intention-to-treat population, with the Kaplan-Meier method. Adverse events were assessed in all patients who received assigned treatment. This study is registered with ClinicalTrials.gov, number NCT02231086. Findings Between April 1, 2015, and Feb 20, 2017, 204 patients were randomly assigned to treatment (102 in each group). In the HIPEC group, two patients withdrew consent after randomisation. In this group, 19 (19%) of 100 patients were diagnosed with peritoneal metastases: nine (47%) during surgical exploration preceding intentional adjuvant HIPEC, eight (42%) during routine follow-up, and two (11%) during diagnostic laparoscopy at 18-months. In the control group, 23 (23%) of 102 patients were diagnosed with peritoneal metastases, of whom seven (30%) were diagnosed by laparoscopy at 18-months and 16 during regular follow-up (therefore making them ineligible for diagnostic laparoscopy). In the intention-to-treat analysis (n=202), there was no difference in peritoneal-free survival at 18-months (80·9% [95% CI 73·3–88·5] for the experimental group vs 76·2% [68·0–84·4] for the control group, log-rank one-sided p=0·28). 12 (14%) of 87 patients who received adjuvant HIPEC developed postoperative complications and one (1%) encapsulating peritoneal sclerosis. Interpretation In patients with T4 or perforated colon cancer, treatment with adjuvant HIPEC with oxaliplatin did not improve peritoneal metastasis-free survival at 18 months. Routine use of adjuvant HIPEC is not advocated on the basis of this trial. Funding Organization for Health Research and Development and the Dutch Cancer Society." @default.
• W2964855288 created "2019-08-13" @default.
• W2964855288 creator A5001958506 @default.
• W2964855288 creator A5002130583 @default.
• W2964855288 creator A5002881692 @default.
• W2964855288 creator A5004704901 @default.
• W2964855288 creator A5005988690 @default.
• W2964855288 creator A5006155689 @default.
• W2964855288 creator A5006256262 @default.
• W2964855288 creator A5006647693 @default.
• W2964855288 creator A5008685422 @default.
• W2964855288 creator A5009257220 @default.
• W2964855288 creator A5009837891 @default.
• W2964855288 creator A5009841763 @default.
• W2964855288 creator A5010086136 @default.
• W2964855288 creator A5013075741 @default.
• W2964855288 creator A5013344790 @default.
• W2964855288 creator A5013432555 @default.
• W2964855288 creator A5014371598 @default.
• W2964855288 creator A5015986746 @default.
• W2964855288 creator A5016446106 @default.
• W2964855288 creator A5016755956 @default.
• W2964855288 creator A5017643108 @default.
• W2964855288 creator A5018257538 @default.
• W2964855288 creator A5018286945 @default.
• W2964855288 creator A5020655761 @default.
• W2964855288 creator A5021161933 @default.
• W2964855288 creator A5021765867 @default.
• W2964855288 creator A5021834422 @default.
• W2964855288 creator A5022541805 @default.
• W2964855288 creator A5022787503 @default.
• W2964855288 creator A5023598501 @default.
• W2964855288 creator A5026151619 @default.
• W2964855288 creator A5026348627 @default.
• W2964855288 creator A5026531183 @default.
• W2964855288 creator A5026906139 @default.
• W2964855288 creator A5029790156 @default.
• W2964855288 creator A5029907141 @default.
• W2964855288 creator A5031203929 @default.
• W2964855288 creator A5031895791 @default.
• W2964855288 creator A5032269563 @default.
• W2964855288 creator A5035256520 @default.
• W2964855288 creator A5035560467 @default.
• W2964855288 creator A5035925842 @default.
• W2964855288 creator A5038875734 @default.
• W2964855288 creator A5040730734 @default.
• W2964855288 creator A5043942519 @default.
• W2964855288 creator A5044683614 @default.
• W2964855288 creator A5045211331 @default.
• W2964855288 creator A5046536264 @default.
• W2964855288 creator A5047180575 @default.
• W2964855288 creator A5050043432 @default.
• W2964855288 creator A5050495040 @default.
• W2964855288 creator A5051871776 @default.
• W2964855288 creator A5051882929 @default.
• W2964855288 creator A5053786012 @default.
• W2964855288 creator A5056187637 @default.
• W2964855288 creator A5057794982 @default.
• W2964855288 creator A5061111119 @default.
• W2964855288 creator A5062450357 @default.
• W2964855288 creator A5064234349 @default.
• W2964855288 creator A5064392216 @default.
• W2964855288 creator A5069825166 @default.
• W2964855288 creator A5070495046 @default.
• W2964855288 creator A5070627170 @default.
• W2964855288 creator A5071097528 @default.
• W2964855288 creator A5073013326 @default.
• W2964855288 creator A5073552513 @default.
• W2964855288 creator A5073560925 @default.
• W2964855288 creator A5074957985 @default.
• W2964855288 creator A5074964050 @default.
• W2964855288 creator A5074970209 @default.
• W2964855288 creator A5075192507 @default.
• W2964855288 creator A5075215007 @default.
• W2964855288 creator A5075540670 @default.
• W2964855288 creator A5075879058 @default.
• W2964855288 creator A5076674657 @default.
• W2964855288 creator A5077405381 @default.
• W2964855288 creator A5079810522 @default.
• W2964855288 creator A5081787468 @default.
• W2964855288 creator A5082610769 @default.
• W2964855288 creator A5084817085 @default.
• W2964855288 creator A5085034913 @default.
• W2964855288 creator A5085209775 @default.
• W2964855288 creator A5085580052 @default.
• W2964855288 creator A5086479144 @default.
• W2964855288 creator A5086751105 @default.
• W2964855288 creator A5086959085 @default.
• W2964855288 creator A5087708892 @default.
• W2964855288 creator A5088241536 @default.
• W2964855288 creator A5091912883 @default.
• W2964855288 date "2019-10-01" @default.
• W2964855288 modified "2023-10-17" @default.
• W2964855288 title "Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial" @default.
• W2964855288 cites W1971567256 @default.
• W2964855288 cites W1973932889 @default.
• W2964855288 cites W1977487863 @default.
• W2964855288 cites W1977844987 @default.

• next